Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

CXCR2 chemokine receptor – a master regulator in cancer and physiology

Trends in Molecular Medicine(2023)10.1016/j.molmed.2023.09.003Source: DataRank Database

CXCR2 chemokine receptor – a master regulator in cancer and physiology is a research paper published in Trends in Molecular Medicine (2023). On theSindex it has a DataRank of 0. It has been cited 84 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access84 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 10.00)OA: greenTopics (24)Linked Datasets (8)DataCite Reuse (8)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Krishna Rajarathnam ORCID,Ann Richmond ORCID,Gwendal Lazennec ORCID

Live enrichment

PubMed:37872025 PMC:PMC10841707 OpenAlex:https://openalex.org/W4387849982

U.S. Department of Veterans Affairs

Grant: 51K6BX005225

U.S. Department of Veterans Affairs

Grant: 101BX002301

National Institutes of Health

Grant: CA116021

National Institutes of Health

Grant: R21AI160613

National Institutes of Health

Grant: CA243326

BLRD VA

Grant: I01 BX002301

BLRD VA

Grant: IK6 BX005225

NCI NIH HHS

Grant: R01 CA116021

NCI NIH HHS

Grant: R01 CA243326

U.S. Department of Veterans Affairs

Ligue Contre le Cancer

FWCI

10.00

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://hal.science/hal-04403865/document

publisherhttps://api.elsevier.com/content/article/PII:S1471491423002186?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1471491423002186?httpAccept=text/plain

repositoryhttps://hal.science/hal-04403865

Fields of Study

Chemokine receptors and signalingImmune cells in cancerImmunotherapy and Immune Responses

MeSH Terms

AnimalsHumansInflammationNeoplasmsNeutrophilsMice, KnockoutReceptors, Interleukin-8BMice

Keywords

CXC chemokine receptorsChemokine receptorBiologyChemokineCancerInflammationImmunologyMedicineCancer researchInternal medicineGlycosaminoglycanneutrophilCxcr2

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma

10.6084/m9.figshare.26401868.v1figshare

Additional file 1 of Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma

10.6084/m9.figshare.26401868figshare

Additional file 2 of Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma

10.6084/m9.figshare.26401983.v1figshare

Additional file 2 of Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma

10.6084/m9.figshare.26401983figshare

Additional file 3 of Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma

10.6084/m9.figshare.26754673.v1figshare

Additional file 3 of Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma

10.6084/m9.figshare.26754673figshare

Additional file 4 of Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma

10.6084/m9.figshare.26754676.v1figshare

Additional file 4 of Pericytes recruited by CCL28 promote vascular normalization after anti-angiogenesis therapy through RA/RXRA/ANGPT1 pathway in lung adenocarcinoma

10.6084/m9.figshare.26754676figshare